. 2020 Oct 7;7(12):ofaa470. doi: 10.1093/ofid/ofaa470

Table 1.

Characteristics at Baseline

						HCV Antibody–Positive
				Anti-HCV-Negative		Group 2		Group 3		Group 4		Group 5
		All		Group 1		Spontaneous Clearers		Chronic Untreated Infection		Successfully Treated		Treated; HCV-RNA-Positive
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All		16 099	100.0	10 091	62.7	722	4.5	3614	22.4	912	5.7	760	4.7
Gender	Male	11 910	74.0	7649	75.8	472	65.4	2548	70.5	679	74.5	562	73.9
	Female	4189	26.0	2442	24.2	250	34.6	1066	29.5	233	25.5	198	26.1
HIV risk	MSM	6248	38.8	5306	52.6	99	13.7	427	11.8	250	27.4	166	21.8
	IDU	4026	25.0	293	2.9	411	56.9	2422	67.0	467	51.2	433	57.0
	Heterosexual	4628	28.7	3770	37.4	134	18.6	498	13.8	124	13.6	102	13.4
	Other	1197	7.4	722	7.2	78	10.8	267	7.4	71	7.8	59	7.8
Ethnic	White	13 743	85.4	8483	84.1	589	81.6	3291	91.1	728	79.8	652	85.8
Origin	Other	2356	14.6	1608	15.9	133	18.4	323	8.9	184	20.2	108	14.2
Region	South	3936	24.4	2220	22.0	147	20.4	1015	28.1	259	28.4	295	38.8
	Central	4336	26.9	2858	28.3	238	33.0	692	19.1	331	36.3	217	28.6
	North	3451	21.4	2493	24.7	131	18.1	591	16.4	134	14.7	102	13.4
	Central East	2132	13.2	1328	13.2	89	12.3	602	16.7	53	5.8	60	7.9
	East	1728	10.7	763	7.6	107	14.8	652	18.0	128	14.0	78	10.3
	Argentina	516	3.2	429	4.3	10	1.4	62	1.7	7	0.8	8	1.1
HBV status	Negative	13 555	84.2	8830	87.5	526	72.9	2834	78.4	757	83.0	608	80.0
	Positive	1214	7.5	744	7.4	114	15.8	254	7.0	61	6.7	41	5.4
	Unknown	1330	8.3	517	5.1	82	11.4	526	14.6	94	10.3	111	14.6
Ever cART	No	2395	14.9	1627	16.1	80	11.1	524	14.5	88	9.6	76	10.0
	Yes	13 704	85.1	8464	83.9	642	88.9	3090	85.5	824	90.4	684	90.0
HIV VL	<500	11 036	68.6	6623	65.6	542	75.1	2431	67.3	795	87.2	645	84.9
Copies/mL	>500	5063	31.4	3468	34.4	180	24.9	1183	32.7	117	12.8	115	15.1
Comorbidities	AIDS	4089	25.4	2735	27.1	199	27.6	867	24.0	139	15.2	149	19.6
	CVD	307	1.9	198	2.0	11	1.5	53	1.5	30	3.3	15	2.0
	NADM	311	1.9	181	1.8	20	2.8	73	2.0	21	2.3	16	2.1
	ESLD	175	1.1	45	0.4	10	1.4	66	1.8	23	2.5	31	4.1
	Hypertension	3443	21.4	2233	22.1	161	22.3	635	17.6	229	25.1	185	24.3
	CKD	108	0.7	34	0.3	9	1.2	32	0.9	23	2.5	10	1.3
		All		Anti-HCV Negative		HCV Antibody Positive
				Group 1		Group 2		Group 3		Group 4		Group 5
						Spontaneous Clearers		Chronic Untreated Infection		Cured		Treated; HCV-RNA-Positive
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All		16 099	100.0	10 091	62.7	722	4.5	3614	22.4	912	5.7	760	4.7
Smoking status	Never	4366	27.1	3462	34.3	112	15.5	635	17.6	205	22.5	137	18.0
	Current	8520	52.9	4675	46.3	471	65.2	32	0.9	440	48.2	423	55.7
	Previous	1470	9.1	913	9.0	72	10.0	450	12.5	125	13.7	85	11.2
	Unknown	1743	10.8	1041	10.3	67	9.3	2511	69.5	142	15.6	115	15.1
Fibrosis	0/1	6468	40.2	3441	34.1	434	60.1	275	7.6	584	64.0	384	50.5
	2	464	2.9	33	0.3	19	2.6	378	10.5	93	10.2	100	13.2
	3	214	1.3	12	0.1	5	0.7	1625	45.0	65	7.1	53	7.0
	4	438	2.7	35	0.3	23	3.2	219	6.1	85	9.3	113	14.9
	Unknown	8515	52.9	6570	65.1	241	33.4	79	2.2	85	9.3	110	14.5
BMI	≤18.5 kg/m²	620	3.9	335	3.3	32	4.4	182	5.0	34	3.7	36	4.7
	18.5–25 kg/m²	8108	50.4	5108	50.6	352	48.8	1509	41.8	418	45.8	333	43.8
	>25 kg/m²	3350	20.8	2198	21.8	157	21.9	2080	57.6	201	22.0	148	19.5
	Unknown	4021	25.0	2450	24.3	180	24.9	539	14.9	259	28.4	243	32.0
Prior HCV	IFN + RBV	1352	80.9							713	78.2	639	84.1
Treatment	DAA + IFN	177	10.6							106	11.6	71	9.3
	DAA only	280	16.7							179	19.6	101	13.3
		Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR
Age, y		41	35–49	41	34–49	42	36–50	40	34–45	48	39–53	47	40–53
CD4, /mm³		443	288–633	437	287–618	460	291–672	410	258–610	543	369–773	550	372–754
Nadir CD4, /mm³		180	73–291	180	71–293	164	57–288	172	76–285	190	78–292	199	102–300
Baseline, mm/yy		01/06	01/01–05/12	01/04	01/01–07/08	03/14	03/02–02/15	02/08	01/01–11/14	01/15	10/14–07/15	12/14	09/14–05/15

Baseline was defined as the latest of January 1, 2001, enrollment to EuroSIDA, known HCV antibody status, and, for those who were HCV antibody–positive, known HCV-RNA status. Spontaneous clearers (HCV antibody–positive, HCV-RNA-negative, untreated); chronic untreated infection (HCV antibody–positive, HCV-RNA-positive, untreated); cured (HCV antibody–positive, HCV-RNA-negative, treated); treated, HCV-RNA-positive (HCV antibody–positive, HCV-RNA-positive, treated). Six hundred twenty-nine persons (45/27/197/177/183 groups 1–5, respectively) had fibrosis defined by biopsy, 1327 (102/71/537/339/278) using Fibroscan, 4807 (3089/285/961/304/168) using APRI, and 821 (285/98/410/7/21) using hyaluronic acid. All comparisons across strata had a P value <.0001 except prior NADM (P = .33), prior CVD (P = .0079), and HCV treatment with IFN + RBV (P = .0023), with DAA + IFN (P = .13) and DAA only (P = .0005).

Abbreviations: BMI, body mass index; cART, combination antiretroviral therapy; CKD, chronic kidney disease; CVD, cardiovascular disease; DAA, direct-acting antivirals; ESLD, end-stage liver disease; HCV, hepatitis C virus; IDU, intravenous drug user; IFN, interferon; IQR, interquartile range; MSM, men who have sex with men; NADM, non-AIDS-defining malignancy; RBV, ribavirin; VL, viral load.